Ejaculation Disorders in Male Patients with Cancer: A Systematic Review and Meta-Analysis of Prevalence.
Por:
Pizzol D, Trott M, Grabovac I, Yang L, Barnett Y, Parris C, McDermott DT, Veronese N, Kronbichler A, Ghayda RA, Soysal P, Jacob L., Tully MA, Koyanagi A, Law CT, Kaya C, Thirumavalavan N, Loeb A, Garolla A, Park S, Shin JI, Ilie PC and Smith L
Publicada:
1 dic 2021
Ahead of Print:
21 jul 2021
Resumen:
PURPOSE: Ejaculatory dysfunction (EjD) and erectile dysfunction after cancer treatment are clinically important complications, but their exact prevalence by various kinds of cancer site and type of treatment is unknown. The aim of this systematic review and meta-analysis was to examine the available evidence and provide pooled estimates for prevalence of EjD and erectile dysfunction in relation to all cancer sites and identify characteristics associated with EjD in cancer patients. MATERIALS AND METHODS: We performed a systematic review and meta-analysis of cross-sectional and case-control studies. We searched 4 electronic databases (Medline®, CINAHL, PsychInfo and Embase®) until July 22, 2020. All retrospective or prospective studies reporting the prevalence of EjD in male patients with cancer were included in this review. A random effects meta-analysis was conducted calculating prevalence proportions with 95% confidence intervals. Prevalence proportions were calculated for the incidences of EjD by cancer site and type of treatment. RESULTS: A total of 64 studies (a total of 10,057 participants) were included for analysis. The most common cancer sites were bladder, colon, testis and rectum. The prevalence rates of EjD after surgical intervention ranged from 14.5% (95% CI 2.2-56.3) in colon cancer to 53.0% (95% CI 23.3-80.7) in bladder cancer. The prevalence rates of erectile dysfunction ranged from 6.8% (95% CI 0.8-39.1) in bladder cancer to 68.7% (95% CI 55.2-79.6) in cancer of the rectum. CONCLUSIONS: In a large study-level meta-analysis, we looked at a high prevalence of EjD and erectile dysfunction at various cancer sites and across different treatment types. Prospective studies of EjD and erectile dysfunction after various kinds of cancer treatments are warranted.
Filiaciones:
Pizzol D:
Italian Agency for Development Cooperation, Khartoum, Sudan
Trott M:
The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK
Grabovac I:
Department of Social and Preventive Medicine, Centre for Public Health, Medical University of Vienna, Vienna, Austria
Yang L:
Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada
Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Barnett Y:
Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK
Parris C:
Biomedical Research Group, School of Life Sciences, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK
McDermott DT:
Faculty of Science and Engineering, Nottingham Trent University, Nottingham, UK
Veronese N:
Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
Kronbichler A:
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
Ghayda RA:
Urology Institute, University Hospitals System, Case Western Reserve University School of Medicine, Cleveland, Ohio
Soysal P:
Department of Geriatric Medicine, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
Jacob L.:
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Barcelona, Spain
Tully MA:
Institute of Mental Health Sciences, School of Health Sciences, Ulster University, Newtownabbey, Northern Ireland
Koyanagi A:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Barcelona, Spain
ICREA, Pg. Lluís Companys 23, Barcelona, Spain
Law CT:
Barts and The London School of Medicine and Dentistry, Queens Mary University of London, London, UK
Kaya C:
Eskisehir City Hospital, Department of Urology, Eskisehir, Turkey
Thirumavalavan N:
Urology Institute, University Hospitals System, Case Western Reserve University School of Medicine, Cleveland, Ohio
Loeb A:
Urology Institute, University Hospitals System, Case Western Reserve University School of Medicine, Cleveland, Ohio
Garolla A:
Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padova, Italy
Park S:
Yonsei University College of Medicine, Seoul, Republic of Korea
Shin JI:
Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Korea
Ilie PC:
Research and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK
Smith L:
The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
Green Submitted
|